Comparative Pharmacology
Head-to-head clinical analysis: ATROPINE versus ROBINUL FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATROPINE versus ROBINUL FORTE.
ATROPINE vs ROBINUL FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), blocking the effects of acetylcholine and other cholinergic agonists. Inhibits vagal activity, increases heart rate, reduces secretions, and relaxes smooth muscle.
Glycopyrrolate is a quaternary ammonium anticholinergic agent that competitively inhibits muscarinic acetylcholine receptors (M1, M2, M3) at postganglionic parasympathetic effector sites, reducing gastrointestinal motility, salivary secretion, and gastric acid secretion.
0.5-1 mg IV/IM/SC every 3-5 minutes as needed, up to a total of 3 mg (adults). For preoperative use, 0.4-0.6 mg IM/IV 30-60 minutes before anesthesia.
1-2 mg orally twice daily; may be increased to 1-2 mg three times daily if needed. Maximum dose: 4 mg daily.
None Documented
None Documented
Clinical Note
moderateBenzatropine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Benzatropine."
Clinical Note
moderateBenzatropine + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Benzatropine."
Clinical Note
moderateBenzatropine + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Benzatropine."
Clinical Note
moderateBenzatropine + Dronedarone
2-4 hours (terminal); prolonged in elderly and neonates; clinically requires dosing every 4-6 hours
Terminal elimination half-life is approximately 2-4 hours in healthy adults; may be prolonged in elderly or renally impaired patients, requiring dose adjustment.
Renal (30-50% unchanged; remainder as inactive metabolites via hydrolysis and glucuronidation); 50-70% of a dose renally excreted as metabolites; <5% fecal
Renal (approx. 50-70% unchanged) and biliary/fecal (approx. 30-50% as unchanged drug and metabolites).
Category C
Category C
Anticholinergic Agent
Anticholinergic Agent
"The metabolism of Dronedarone can be decreased when combined with Benzatropine."